Lizuvira-200 Capsule 40's
About Lizuvira-200 Capsule 40's
Lizuvira-200 Capsule 40's belongs to a class of drugs called antiviral agents indicated for the mild to the moderate treatment of Covid-19. Coronavirus disease/Covid-19, also known as SARS-CoV-2 (Severe Acute Respiratory Syndrome Corona Virus 2), is an infectious disease caused by the coronavirus. Its symptoms include fever and cough and, in some cases, progressing to pneumonia and respiratory failure.
Lizuvira-200 Capsule 40's contains Molnupiravir, a protease inhibitor. It works by interfering with a protein known as protease, which is necessary for the virus-infected cells to generate new viruses. As a result, the resulting virus particles have faulty genetic material and can no longer reproduce. Thereby, Lizuvira-200 Capsule 40's lowers virus load in the body and helps treat the infection.
Take Lizuvira-200 Capsule 40's as prescribed. To treat your condition effectively, you are advised to take Lizuvira-200 Capsule 40's for as long as your doctor has prescribed it. In some cases, Lizuvira-200 Capsule 40's may cause nausea, vomiting, diarrhoea, headache, and dizziness. Most of these side effects do not require medical attention and resolve gradually over time. However, if the side effects persist or worsen, please consult a doctor.
Women of child-bearing potential must use effective contraception during the treatment and for 4days after the last dose. Please seek medical advice from the doctor before taking Lizuvira-200 Capsule 40's if you are pregnant. Breastfeeding should be discontinued during the treatment and for 4days after the last dose. Lizuvira-200 Capsule 40's may cause dizziness, so drive with caution. It is unknown whether consuming alcohol with Lizuvira-200 Capsule 40's is safe. However, it is best to avoid alcohol consumption as it may cause increased dizziness. Keep your healthcare professional updated on your medical condition and medications to rule out any interactions.
Uses of Lizuvira-200 Capsule 40's
Medicinal Benefits
Lizuvira-200 Capsule 40's is an experimental antiviral medication that lowers the risk of hospitalisation or death in patients with mild or moderate covid-19. Lizuvira-200 Capsule 40's is a potent protease inhibitor that interferes with a protein (protease) required by virus-infected cells to generate new viruses. As a result, Lizuvira-200 Capsule 40's helps reduce viral load in the body and aids in infection therapy.
Directions for Use
Storage
Side Effects of Lizuvira-200 Capsule 40's
Drug Warnings
Please do not take Lizuvira-200 Capsule 40's if you are allergic to any of its ingredients. Women of child-bearing potential must use effective contraception during the treatment and for 4days after the last dose. Please seek medical advice from the doctor before taking Lizuvira-200 Capsule 40's if you are pregnant. Breastfeeding should be discontinued during the treatment and for 4days after the last dose. Lizuvira-200 Capsule 40's may cause dizziness, so drive with caution. It is unknown whether consuming alcohol with Lizuvira-200 Capsule 40's is safe. However, it is best to avoid alcohol consumption as it may cause increased dizziness. Keep your doctor updated on your medical condition and medications to rule out any interactions.
Drug Interactions
Drug-Drug Interactions: No interactions were found/established.
Drug-Food Interactions: No interactions were found/established.
Drug-Disease Interactions: No interactions were found/established.
Habit Forming
Diet & Lifestyle Advise
Special Advise
Disease/Condition Glossary
COVID-19: COVID-19 disease is an infectious disease caused by a coronavirus. It is also known as SARS-CoV-2 (Severe Acute Respiratory Syndrome Corona Virus 2). Coronavirus belongs to the RNA virus family and contains crown-like projections on its surface. The virus spreads through droplets produced by an infected person's cough, sneeze, or heavy breathing. Coronavirus sickness is characterised by dry cough, dyspnea, shortness of breath, fever, loss of taste and smell, diarrhoea, body pains, headache, and sore throat.